Bavarian Nordic rejects claim from Helmholtz Zentrum München
(Thomson Reuters ONE) - Kvistgaard, Denmark, August 31, 2009 - Bavarian Nordic A/S (OMX:BAVA) announced today that it has been notified by the ICCInternational Court of Arbitration that a request for arbitration hasbeen received from Helmholtz Zentrum München, DeutschesForschungszentrum für Gesundheit und Umwelt GmbH (formerly also knownas GSF).The arbitration request is based on two old agreements with BavarianNordic from 1994 and 1997 regarding a collaboration on certainrecombinant vaccines, which was formally terminated in 2001. Theagreements do not encompass the MVA-BN® patents but provide BavarianNordic with exclusive royalty bearing license to specific patents onrecombinant vaccines and include clauses dealing with transfer ofknow how pertaining thereto. Nevertheless, Helmholtz Zentrum Münchennow in 2009 claims rights to royalties on Bavarian Nordic's MVA-BN®based vaccines, including IMVAMUNE®.Anders Hedegaard, President & CEO of Bavarian Nordic said: "We viewthis claim based on the old agreements as being baseless and withoutmerit. We are confident that we will prevail should this claimcontinue at the Court of Arbitration."Asger AamundChairmanContactAnders Hedegaard, President & CEO. Phone +45 23 20 30 64http://hugin.info/100065/R/1338207/319203.pdfThis announcement was originally distributed by Hugin. The issuer is solely responsible for the content of this announcement.
Datum: 31.08.2009 - 11:31 Uhr
Sprache: Deutsch
News-ID 5280
Anzahl Zeichen: 0
contact information:
Town:
London
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 350 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Bavarian Nordic rejects claim from Helmholtz Zentrum München"
steht unter der journalistisch-redaktionellen Verantwortung von
Bavarian Nordic A/S (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
